Equities Analysts Issue Forecasts for BCRX FY2026 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for BioCryst Pharmaceuticals in a note issued to investors on Wednesday, October 15th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings per share of $0.02 for the year, down from their prior forecast of $0.31. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals' FY2027 earnings at $0.34 EPS and FY2028 earnings at $0.85 EPS.

Other equities research analysts have also recently issued reports about the company. JMP Securities lifted their target price on BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a "market outperform" rating in a report on Wednesday. Bank of America lifted their target price on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Tuesday, July 1st. Wedbush lifted their target price on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an "outperform" rating in a report on Monday, June 30th. Cantor Fitzgerald lifted their target price on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an "overweight" rating in a report on Wednesday. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $13.00 target price on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $19.18.

BioCryst Pharmaceuticals Trading Down 1.3%

Shares of BCRX stock opened at $6.72 on Friday. BioCryst Pharmaceuticals has a 12-month low of $6.00 and a 12-month high of $11.31. The stock's 50-day moving average price is $7.87 and its 200-day moving average price is $8.64. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of -37.33, a price-to-earnings-growth ratio of 1.43 and a beta of 1.05.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.12. The business had revenue of $163.35 million for the quarter, compared to the consensus estimate of $149.59 million. BioCryst Pharmaceuticals's revenue was up 49.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.06) earnings per share.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Arrowstreet Capital Limited Partnership boosted its position in shares of BioCryst Pharmaceuticals by 2,103.7% during the second quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company's stock valued at $38,336,000 after buying an additional 4,084,403 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of BioCryst Pharmaceuticals by 25,631.2% during the second quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company's stock valued at $32,441,000 after buying an additional 3,606,566 shares during the period. Millennium Management LLC boosted its position in shares of BioCryst Pharmaceuticals by 382.6% during the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company's stock valued at $28,597,000 after buying an additional 3,022,769 shares during the period. Qube Research & Technologies Ltd boosted its position in shares of BioCryst Pharmaceuticals by 152.3% during the second quarter. Qube Research & Technologies Ltd now owns 2,373,489 shares of the biotechnology company's stock valued at $21,266,000 after buying an additional 1,432,824 shares during the period. Finally, Nuveen LLC purchased a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at approximately $10,677,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

Insider Buying and Selling

In related news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the transaction, the director owned 65,352 shares in the company, valued at approximately $556,145.52. This trade represents a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.10% of the company's stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.